A new case of t(16;21)(q24;q22) in a secondary AML-M2 following breast cancer therapy

Hélène Bruyère, Wilson Yeung, Peter Tsang Affiliation

Department of Pathology and Laboratory Medicine, Vancouver General Hospital, UBC, Canada, Helene.Bruyere@vch.ca and Division of Hematology, Vancouver General Hospital, UBC, Canada

Previous history

Preleukaemia

Malignant disease

Breast cancer diagnosed in 2002, treated with radical mastectomy, chemotherapy with cyclophosphamide, epirubicin, 5-fluoro-uracil, radiotherapy.

Inborn condition

Clinics case report

Age

61 yrs

Sex

Liver

Spleen

Lymph nodes

Cns involv

Blood data

Wbc

2.4

10.7

Platelets

Blasts

Bone marrow

Neutrophils 0.05 ; Band cells 0.05 ; Metamyelocytes 0.13 ; Myelocytes 0.02 ; Promyelocytes 0.02 ; Blasts 0.51 ; Late normoblasts 0.13 ; Plasma cells 0.01 ; Lymphocytes 0.05 ; Monocytes 0.01 ; Eosinophils 0.02

Cyto path

Cytology

AML-M2

Immunophenotype

Positive for HLA-DR, CD34, CD117, CD13, CD33, MPO, CD56 and CD19 ; Partial Tdt ; Negative for CD7

Precise diagnosis

Hypoplastic AML, therapy related

Survival data

Date diagnosis

04-2005

Treatment

Three cycles of AraC and Danuribicin ; Related bone marrow transplantation planned for September 2005

Complete remission

Yes, 05-2005

Status

Date last follow

07-2005

Survival

3 +

Karyotype

Sample

Bone marrow

Culture time

Banding

GTG

Results

47,XX,+8,t(16;21)(q24;q22)[13]/46,XX[3]

Images

Partial karyotype showing the t(16;21) and a +8

Comments section

Comments

All of the nine patients whose treatments were reported (3-9), plus the current case, were treated with a combination of alkylating agents and topoisomerase II inhibitors, +/- radiotherapy.

Bibliography

Pubmed ID	Last Year	Title	Authors
2758395	1989	Cytogenetics of childhood acute nonlymphocytic leukemia.	Raimondi SC et al
7819102	1994	Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies.	Nylund SJ et al
8043877	1994	Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma.	Traweek ST et al
8932000	1996	Secondary acute myeloblastic leukemia with t(16;21) (q24;q22). involving the AML1 gene.	Berger R et al
9216714	1997	A recurrent translocation, t(16;21)(q24;q22), associated with acute myelogenous leukemia: identification by fluorescence in situ hybridization.	Shimada M et al
9631585	1998	A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide.	Takeda K et al
10995019	2000	AML1-MTG16 fusion gene in therapy-related acute leukemia with t(16;21)(q24;q22): two new cases.	Salomon-Nguyen F et al
11224496	2001	AML1/MTG16 fusion gene from a t(16;21)(q24;q22) translocation in treatment-induced leukemia after breast cancer.	La Starza R et al
11999578	2002	A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene.	Kondoh K et al
11921272	2002	21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop.	Slovak ML et al

Citation

Hélène Bruyère, Wilson Yeung, Peter Tsang

A new case of t(16;21)(q24;q22) in a secondary AML-M2 following breast cancer therapy

Atlas Genet Cytogenet Oncol Haematol. 2005-08-01

Online version: http://atlasgeneticsoncology.org/case-report/208811/a-new-case-of-t(16;21)(q24;q22)-in-a-secondary-aml-m2-following-breast-cancer-therapy